vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $66.0M, roughly 1.2× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 10.2%, a 29.2% gap on every dollar of revenue.
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
AMSF vs SLNO — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $66.0M |
| Net Profit | $8.1M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | — | 33.5% |
| Net Margin | 10.2% | 39.4% |
| Revenue YoY | 10.3% | — |
| Net Profit YoY | -9.0% | 134.0% |
| EPS (diluted) | $0.43 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | — | ||
| Q3 25 | $82.0M | $66.0M | ||
| Q2 25 | $81.1M | $32.7M | ||
| Q1 25 | $72.6M | — | ||
| Q4 24 | $74.0M | — | ||
| Q3 24 | $78.7M | — | ||
| Q2 24 | $75.8M | — |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $13.8M | $26.0M | ||
| Q2 25 | $14.0M | $-4.7M | ||
| Q1 25 | $8.9M | — | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | — | ||
| Q2 24 | $11.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | — | ||
| Q3 25 | 21.3% | 33.5% | ||
| Q2 25 | 21.5% | -20.0% | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 22.6% | — | ||
| Q2 24 | 18.1% | — |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 16.9% | 39.4% | ||
| Q2 25 | 17.2% | -14.4% | ||
| Q1 25 | 12.3% | — | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | — | ||
| Q2 24 | 14.5% | — |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | — | ||
| Q3 25 | $0.72 | $0.47 | ||
| Q2 25 | $0.73 | $-0.09 | ||
| Q1 25 | $0.47 | — | ||
| Q4 24 | $0.69 | — | ||
| Q3 24 | $0.75 | — | ||
| Q2 24 | $0.57 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $494.8M |
| Total Assets | — | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | — | ||
| Q3 25 | $54.7M | $498.9M | ||
| Q2 25 | $48.5M | $286.8M | ||
| Q1 25 | $44.8M | — | ||
| Q4 24 | $44.1M | — | ||
| Q3 24 | $63.7M | — | ||
| Q2 24 | $30.6M | — |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | — | ||
| Q3 25 | $274.8M | $494.8M | ||
| Q2 25 | $265.6M | $240.1M | ||
| Q1 25 | $260.8M | — | ||
| Q4 24 | $257.3M | — | ||
| Q3 24 | $314.4M | — | ||
| Q2 24 | $301.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | $599.9M | ||
| Q2 25 | $1.2B | $332.3M | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | — | ||
| Q3 25 | $10.7M | $43.5M | ||
| Q2 25 | $-8.4M | $-12.6M | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | $43.5M | ||
| Q2 25 | $-9.5M | $-12.6M | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $23.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | 65.8% | ||
| Q2 25 | -11.7% | -38.6% | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 1.3% | 0.0% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | 1.67× | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
